Return To Mondaq Homepage Food, Drugs, Healthcare, Life Sciences
Preview most recent added content
Receiving the free weekly news alert
Click to ask the author from Venable LLP a question

United States: FDA Issues Warning Letter to Lancȏme USA

17 September 2012

On September 7, 2012, the FDA issued a Warning Letter to Lancȏme USA, a subsidiary of L'Oreal, advising that claims made on Lancȏme's website for a series of products sold under names containing "Youth Activating" and "Regenerating and Reconstructing" caused the products to be drugs under the Food, Drug, and Cosmetic Act.1  While in its letter the FDA identified the specific claims listed below, it noted that these were only "some of the claims" the FDA observed on Lancȏme's website that were problematic. The FDA gave Lancȏme the standard 15-business-day period within which to respond to the Warning Letter.

Of note here is that the Warning Letter was issued by the FDA's Center for Food Safety and Applied Nutrition (CFSAN) and not one of the agency's Regional Field Offices, which have been responsible for most of the Warning Letters issued to cosmetic companies whose claims had crossed over what is popularly called the "drug/cosmetic line," thereby rendering the products drugs that were unlawfully on the market. The significance of this Lancȏme Warning Letter, beyond the specific claims issues that it raises, is the fact that the letter was issued directly by CFSAN, where the Office of Cosmetics and Colors, which has primary regulatory responsibility for cosmetic products, is located. This could indicate that the Office of Cosmetics and Colors, which has been the subject of Congressional criticism because of its inactivity in recent years, will now become more active. A second Warning Letter, issued to Greek Island Labs on September 7, 2012 as well, suggests we should expect greater activity.

It will probably take time before we can be certain whether this is a single Warning Letter or whether the Office of Cosmetics and Colors is positioning itself to become more active in the claims area - taking on the role it took back in the late 1980s, when the Office was responsible for sending over thirty Warning Letters to larger companies, advising them that their marketing claims transformed their products into illegal drugs. It is important to keep in mind that, in addition to the Warning Letters in the late 1980s, the FDA at that time sent inspectors out to make rounds to all of the major cosmetic companies to "encourage them" to drop the claims. There were threatened seizures at that time and at least one customs detention. This activity was the genesis of the FDA's current import alert for "anti-aging" products.

Because federal action has been shown to encourage consumer class action lawsuits, we recommend that organizations review their claims, continue to be vigilant, and watch to see whether the Lancȏme letter will be a singular incident or an indication of a new initiative on the part of the FDA. 

The Lancȏme website claims identified in the Warning Letter include the following:

Génifique Youth Activating Concentrate, Génifique Eye Youth Activating Eye Concentrate, and Génifique Cream Serum Youth Activating Cream Serum:

  • "[B]oosts the activity of genes and stimulates the production of youth proteins."

Génifique Repair Youth Activating Night Cream:

  • "[B]oosts the activity of genes."

Absolue Precious Cells Advanced Regenerating and Reconstructing Cream SPF 15 Sunscreen:

  • "A powerful combination of unique ingredients - Reconstruction Complex and Pro-Pro-Xylane", ¢, a patented scientific innovation - has been shown to improve the condition around the stem cells and stimulate cell regeneration to reconstruct skin to a denser quality."
  • "See significant deep wrinkle reduction in UV damaged skin, clinically proven."

Absolue Eye Precious Cells Advanced Regenerating and Reconstructing Eye Cream and Absolue Night Precious Cells Advanced Regenerating and Reconstructing Night Cream:

  • "A powerful combination of unique ingredients - Reconstruction Complex and Pro-Pro-Xylane", ¢, a patented scientific innovation - has been shown to improve the condition around the stem cells and stimulate cell regeneration to reconstruct skin to a denser quality."

RénergieMicrolift Eye R.A.R.E.⢠Intense Repositioning Eye Lifter:

  • "Immediate lifting, lasting repositioning. Inspired by eye-lifting surgical techniques...helps recreate a younger, lifted look in the delicate eye area."
  • "[U]nique R.A.R.E. oligopeptide helps to re-bundle collagen."

Click here to read the Warning Letter sent to Lancȏme.

Click here to read the Warning Letter sent to Greek Island Labs.

Footnotes

1. We note that the FDA considers website content to be labeling in certain circumstances (e.g., if a company promotes a regulated product on its website and allows consumers to purchase the product directly from the website, or if the product contains a statement that refers consumers to the website for additional information about a claim). However, even if the website is not considered labeling, the FDA can use website claims as evidence of the intended use of the product, which determines into which regulatory category the product falls.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Specific Questions relating to this article should be addressed directly to the author.

View Popular Related Articles on Food, Drugs, Healthcare, Life Sciences from USA
Wake Up Call For Providers
In April 2013, the U.S. Department of Justice announced the settlement of five investigations with healthcare providers.
CMS And OIG Propose Changes To The Electronic Health Records Exception And Safe Harbor
The Centers for Medicare & Medicaid Services and the Department of Health and Human Services Office of Inspector General have recently published parallel proposed rules revising, respectively, the Stark exception and Anti-Kickback safe harbor concerning electronic health record items and services.
CMS Proposes To Increase Awards For Non-Qui Tam Whistleblowers
CMS wants to change the way that it rewards non-qui tam whistleblowers who report alleged fraudulent or unlawful conduct related to Medicare or Medicaid.
Recent Omnibus Rule Expands Reach Of HIPAA
By now you may have heard the news about a number of changes on the horizon for the Health Insurance Portability and Protection Act.
Health Care Reform Implementation Update - April 26, 2013
Marilyn Tavenner received bipartisan support from members of the Senate Committee on Finance in her confirmation hearing to lead the Centers for Medicare and Medicaid Services (CMS) though a full Senate vote is being held up, the president released his FY 2014 budget proposal with health care reform and specified reimbursement reductions to providers and manufacturers totaling $400 billion over 10 years sprinkled throughout it, and Department of Health and Human Services (HHS) Secretary Sebelius
OCR Publishes HIPAA Guides For Providers And Consumers
Understanding the complexities of the Health Insurance Portability and Accountability Act of 1996 (HIPAA) Privacy and Security Rules is often a challenge for health care providers and consumers.
Federal Circuit Finds Prosecution History Disclaimer In Enablement Arguments
A discussion relating to a recent case, where the Federal Circuit upheld a narrow claim interpretation based on prosecution history disclaimer.
Revocation Of EHR Certification Rocks Industry
The news from the Office of the National Coordinator for Health IT (ONC) about the revocation of the electronic health record (EHR) certifications of two EHR products that had previously been certified will have tremendous ramifications not only on the EHR vendor losing its certifications, but generally on providers and vendors as well.
Login
Register for Free
First Time Here?

 
Mondaq Topics
 
Our Services
 
About This Site
 
Advertise with Us
Unsubscribe
Copyright
Close Me
Register for Access and our Free Biweekly Alert
About You
Title Forename Surname
Email Address
Company Name
Password Confirm
Mondaq Topics --Select your interest
Accounting and Audit Anti-trust/Competition Law Consumer Protection Corporate/Commercial Law
Criminal Law Employment and HR Energy and Natural Resources Environment
Family and Matrimonial Finance and Banking Food, Drugs, Healthcare, Life Sciences Government, Public Sector
Immigration Insolvency/Bankruptcy, Re-structuring Insurance Intellectual Property
International Law Litigation, Mediation & Arbitration Media, Telecoms, IT, Entertainment Privacy
Real Estate and Construction Strategy Tax Transport
Wealth Management  

Regions
Worldwide Updates Africa Asia Asia Pacific
Australasia Canada Caribbean Europe
European Union Latin America Middle East U.K.
United States  

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.


Mondaq 1994-2013.
All Rights Reserved